Guess which ASX 200 healthcare share just rocketed 11% on 'groundbreaking trial'

Up 67% in a year, investors are sending the ASX 200 healthcare share soaring again today.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare share is leaving those gains wanting.

Shares in the biopharmaceutical company closed on Wednesday trading for $20.71.

The stock then entered a trading halt pending an announcement on the results of its phase 2 clinical trial for one of its drug candidates intended to treat patients with Pitt Hopkins syndrome.

The ASX 200 healthcare share exited that trading halt this morning following on that announcement, which saw shares leap to $23.07 apiece, up 11.4%.

After some likely profit-taking, shares are currently changing hands for $22.67 apiece, up 9.5%.

Any guesses?

If you said Neuren Pharmaceuticals Ltd (ASX: NEU), go to the front of the virtual class.

Created with Highcharts 11.4.3Neuren Pharmaceuticals PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's what's spurring investor interest on Monday.

ASX 200 healthcare share soars on significant results improvements

The Neuren Pharmaceuticals share price is leaping higher today after the company reported on the top-line results from its phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS).

PTHS can be severely debilitating for patients, yet there are currently no approved treatments for the disease.

And investors are bidding up the ASX 200 healthcare share after Neuren Pharmaceuticals noted a "statistically significant improvement" was observed relative to the baseline following treatment. That improvement was observed by both caregivers and clinicians across all four efficacy measures designed to assess the core characteristics of PTHS.

Patients showed improvements in areas including communication, social interaction, cognition and motor abilities.

Nine out of 11 children assessed by clinicians showed improvement, while eight out of 11 children assessed by caregivers showed improvement.

NNZ-2591 was also reported to be safe and well tolerated, with no serious or severe adverse events during the phase 2 trial.

Commenting on the clinical trial results sending the ASX 200 healthcare share soaring today, Neuren Pharmaceuticals CEO Jon Pilcher said:

We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need, and we can now continue towards our goal of developing a first approved treatment.

We are very grateful to the people in the Pitt Hopkins community and at the trial sites in the United States who enabled the successful completion of this extremely challenging, but groundbreaking trial.

Nancy Jones, Neuren vice president of Clinical Development added:

The consistent results on the PTHS specific assessments affirm the need for syndrome specific measurements in severe neurodevelopmental disorders where measures that were developed for broader populations may not be as appropriate.

Neuren Pharmaceuticals share price snapshot

With today's intraday gains factored in, the ASX 200 healthcare share is up an impressive 67% since this time last year.

Should you invest $1,000 in Neuren Pharmaceuticals Limited right now?

Before you buy Neuren Pharmaceuticals Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Neuren Pharmaceuticals Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rocky but positive start to the week's trading this Monday.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Share Gainers

Why APA, Aussie Broadband, Neuren, and NIB shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

A runner high-fives as he crosses the finish line in pole position
Share Gainers

Here are the top 10 ASX 200 shares today

It was a woeful end to a woeful week this Friday for ASX investors.

Read more »

Siblings jumping on a trampoline.
Share Gainers

3 ASX 200 stocks rocketing higher in this week's falling market

These three ASX 200 outperformers have surged 17% to 28% this week!

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Share Gainers

Why Domain, Mayne Pharma, QBE, and Telix shares are jumping today

These shares are ending the week with a bang. Here's why they are jumping.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an awful Thursday for ASX investors.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Megaport, Nanosonics, Telstra, and Universal Store shares are storming higher today

These shares are catching the eye on Thursday with strong gains.

Read more »